Mehta Rinku V, Malcom Pamela J, Chang R Jeffrey
Department of Reproductive Medicine, University of California, San Diego, School of Medicine, 9500 Gilman Drive, La Jolla, California 92093-0633, USA.
J Clin Endocrinol Metab. 2006 Sep;91(9):3503-6. doi: 10.1210/jc.2006-0752. Epub 2006 Jun 27.
Previously, we have shown that women with polycystic ovary syndrome (PCOS) exhibit an exaggerated serum estradiol (E(2)) response to recombinant human FSH (rhFSH) (150 IU) compared with similarly treated normal women. This enhanced granulosa cell responsiveness is consistent with excessive follicular development after gonadotropin therapy and the corresponding risk of ovarian hyperstimulation syndrome. In vitro studies have shown that granulosa cells treated with androgens display greater FSH-induced E(2) production than untreated cells, suggesting a role for androgens in granulosa cell responsiveness.
This study was conducted to determine whether blockade of androgen action in PCOS women by administration of the antiandrogen flutamide would alter E(2) responses to rhFSH.
We conducted a prospective cohort study.
We studied 11 women with PCOS at an institutional general clinical research center.
On study d 1, each subject received 150 IU rhFSH iv. Frequent blood samples were obtained over 24 h. After completion of rhFSH stimulation, each subject was treated with flutamide, 125 mg, twice daily, for 6 wk. Thereafter, the rhFSH stimulation test was repeated.
Baseline and stimulated E(2) levels before and after treatment were assayed.
Mean baseline and maximally stimulated E(2), integrated E(2) response, and fold change in E(2) were not different before and after treatment. Levels of testosterone, androstenedione, progesterone, 17-hydroxyprogesterone, estrone, and SHBG before and after treatment were unchanged. Baseline dehydroepiandrosterone sulfate levels declined significantly after flutamide therapy.
These findings indicate that in women with PCOS, the E(2) hyperresponsiveness to FSH may not be attributable to increased circulating androgens.
此前,我们已经表明,与接受同样治疗的正常女性相比,多囊卵巢综合征(PCOS)女性对重组人促卵泡激素(rhFSH,150IU)的血清雌二醇(E₂)反应过度。这种颗粒细胞反应性增强与促性腺激素治疗后卵泡过度发育以及卵巢过度刺激综合征的相应风险一致。体外研究表明,用雄激素处理的颗粒细胞比未处理的细胞表现出更高的FSH诱导的E₂产生,提示雄激素在颗粒细胞反应性中起作用。
本研究旨在确定通过给予抗雄激素氟他胺阻断PCOS女性的雄激素作用是否会改变对rhFSH的E₂反应。
我们进行了一项前瞻性队列研究。
我们在一个机构的综合临床研究中心研究了11名PCOS女性。
在研究第1天,每位受试者静脉注射150IU rhFSH。在24小时内频繁采集血样。rhFSH刺激完成后,每位受试者接受氟他胺治疗,125mg,每日两次,共6周。此后,重复rhFSH刺激试验。
测定治疗前后的基线和刺激后的E₂水平。
治疗前后的平均基线和最大刺激E₂、E₂综合反应以及E₂的变化倍数无差异。治疗前后的睾酮、雄烯二酮、孕酮、17-羟孕酮、雌酮和性激素结合球蛋白水平未改变。氟他胺治疗后基线硫酸脱氢表雄酮水平显著下降。
这些发现表明,在PCOS女性中,E₂对FSH的高反应性可能不归因于循环雄激素增加。